Kymera Therapeutics Reports Q3 2026 Results and Positive Phase I Data for KT-579
Kymera Therapeutics (KYMR) reported its third-quarter 2026 financial results, highlighted by strong clinical progress in its immunology pipeline. The company shared positive Phase I data for KT-579, an IRF5 degrader, demonstrating high median degradation levels exceeding 90% and significant inhibition of inflammatory cytokines without serious adverse events. Additionally, the BROADEN 2 Phase IIb study for KT-621 in atopic dermatitis has completed its placebo-controlled portion, with data expected by the end of 2026. Financially, Kymera reported a quarterly net loss of $132.0 million, up from $82.2 million in the prior year, driven largely by increased R&D spending of $128.5 million. Despite the widening loss, the company maintains a robust liquidity position with $1.6 billion in cash and investments, providing a projected operational runway into 2029. Management remains focused on transitioning its oral immunology portfolio toward late-stage clinical trials.
Topics: asthma atopic dermatitis biotechnology clinical trials drug development R&D expenses
Read the full article at Motley Fool
Part of the story Definium Therapeutics Reports Positive Phase 3 Clinical Results and Strong Cash Position for Q3 2026 (11 articles)